B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it can affect people of any age. CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to address this challenge and improve CAR T therapy’s effectiveness.
Go to Source
https://medicalxpress.com/rss-feed/